LB Pharmaceuticals closes $75M Series C as it begins PhII schizophrenia trial
24 Jan 2024
Phase 2
LB Pharmaceuticals, a schizophrenia biotech developing a new version of a decades-old medicine, has closed a $75 million Series C raise and it began a Phase II trial last month, a source familiar with the company confirmed to Endpoints News.
The New York City biotech has raised a total of about $122 million since it was formed, per the source. The company had raised about $35 million last summer and reached its ultimate $75 million Series C target this month.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.